RecruitingNCT05788432
Sequent Extended Study
Sequent Please Neo Extended Post-Market Clinical Follow-up Study
Sponsor
Fundación EPIC
Enrollment
2,028 participants
Start Date
Mar 28, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.
- Informed Consent Signed.
Exclusion Criteria2
- Patient life expectancy less than 12 months.
- Contraindication for antiplatelet therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICESequent Please Neo
Patients in whom treatment with (Sequent Please Neo) has been attempted
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05788432
Related Trials
Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions
NCT067368998 locations
Coroflex® ISAR NEO PMCF Study
NCT0569873222 locations
Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease
NCT067102101 location
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT0542737043 locations
Scaffold in Emilia Romagna and in the MAGIC Network
NCT0332796117 locations